attention deficit hyperactivity disorder, ADHD
Conditions
Interventions
None listed
Sponsors
Takeda Pharmaceutical Company Limited.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subject eligibility is determined based on the following criteria before inclusion in the study: (1) Confirmed diagnosis of ADHD -Patients diagnosed with ADHD as per DSM-5 -CAARS (T score: 65 or higher ) -AQ-J Score: < 33 -JART score: 85 or higher (2) Typical developer -The subject has no history of psychiatric disorders. -The subject has no psychiatric illness as confirmed by a structured interview in accordance with DSM-5. In this case, M.I.N.I. is used secondarily. -CAARS (T score: < 65) -AQ-J Score: < 33 -JART score: 85 or higher (1)(2) Common -In the opinion of the investigator or sub-investigator, the subject is capable of understanding and complying with protocol requirements. -The subject signs and dates a written, informed consent form prior to the initiation of any study procedures. -The subject is aged 20 to 50 years, inclusive, at the time of informed consent. -The subject is native Japanese and can conduct interviews (conversations with healthcare professionals).
Exclusion criteria
Exclusion criteria: Any subject who meets any of the following criteria will not qualify for entry into the study: -The subject is, in the opinion of the physician, unable to participate in the study due to deafness, dysarthria, aphasia, etc. -Cognitive impairment due to a nervous system disorder (Epilepsy, stroke, etc.) or other disorders such as head trauma, or a diagnosis of dementia -The subject has a diagnosis of ASD. -The subject has a diagnosis of psychiatric illness, including anxiety, obsessive-compulsive and related disorders, traumatic and stress-related disorders, depression, bipolar disorder, schizophrenia spectrum disorder, or limited learning and intellectual disability. -Other cases where the investigator or sub-investigator judges it difficult to continue the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity, specificity, and accuracy of the following AI prediction model | — |
Countries
Japan
Contacts
Public ContactNozomi Kamijo
Takeda Pharmaceutical Company Limited. Japan Medical Office
Outcome results
None listed